FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009050298> ?p ?o ?g. }

• W2009050298 endingPage "1153.e9" @default.
• W2009050298 startingPage "1144" @default.
• W2009050298 abstract "Backgroundβ2-Adrenergic receptor (β2AR) agonists are critical treatments for asthma. However, receptor desensitization can lead to loss of therapeutic effects. Although desensitization to repeated use of β2-agonists is well studied, type 2 inflammation could also affect β2AR function.ObjectiveWe sought to evaluate the effect of the type 2 cytokine IL-13 on β2AR desensitization in human airway epithelial cells (HAECs) and determine whether 15-lipoxygenase-1 (15LO1) binding with phosphatidylethanolamine-binding protein 1 (PEBP1) contributes to desensitization through release of G protein receptor kinase 2 (GRK2).MethodsHAECs in air-liquid interface culture with or without IL-13 (48 hours) or isoproterenol hydrochloride (ISO; 30 minutes) pretreatment were stimulated with ISO (10 minutes). Cyclic adenosine 3, 5-monophosphate (cAMP) levels were measured using ELISA, and β2AR and GRK2 phosphorylation was measured using Western blotting. Short interfering RNA was used for 15LO1 knockdown. Interactions of GRK2, PEBP1, and 15LO1 were detected by means of immunoprecipitation/Western blotting and immunofluorescence. HAECs and airway tissue from control subjects and asthmatic patients were evaluated for I5LO1, PEBP1, and GRK2.ResultsPretreatment with ISO or IL-13 decreased ISO-induced cAMP generation compared with ISO for 10 minutes alone paralleled by increases in β2AR and GRK2 phosphorylation. GRK2 associated with PEBP1 after 10 minutes of ISO in association with low phosphorylated GRK2 (pGRK2) levels. In contrast, in the presence of IL-13 plus ISO (10 minutes), binding of GRK2 to PEBP1 decreased, whereas 15LO1 binding and pGRK2 levels increased. 15LO1 knockdown restored ISO-induced cAMP generation. These findings were recapitulated in freshly brushed HAECs from cells and tissue of asthmatic patients.ConclusionIL-13 treatment of HAECs leads to β2AR desensitization, which involves 15LO1/PEBP1 interactions to free GRK2, and allows it to phosphorylate (and desensitize) β2ARs, suggesting that the beneficial effects of β2-agonists could be blunted in patients with type 2 associated asthma. β2-Adrenergic receptor (β2AR) agonists are critical treatments for asthma. However, receptor desensitization can lead to loss of therapeutic effects. Although desensitization to repeated use of β2-agonists is well studied, type 2 inflammation could also affect β2AR function. We sought to evaluate the effect of the type 2 cytokine IL-13 on β2AR desensitization in human airway epithelial cells (HAECs) and determine whether 15-lipoxygenase-1 (15LO1) binding with phosphatidylethanolamine-binding protein 1 (PEBP1) contributes to desensitization through release of G protein receptor kinase 2 (GRK2). HAECs in air-liquid interface culture with or without IL-13 (48 hours) or isoproterenol hydrochloride (ISO; 30 minutes) pretreatment were stimulated with ISO (10 minutes). Cyclic adenosine 3, 5-monophosphate (cAMP) levels were measured using ELISA, and β2AR and GRK2 phosphorylation was measured using Western blotting. Short interfering RNA was used for 15LO1 knockdown. Interactions of GRK2, PEBP1, and 15LO1 were detected by means of immunoprecipitation/Western blotting and immunofluorescence. HAECs and airway tissue from control subjects and asthmatic patients were evaluated for I5LO1, PEBP1, and GRK2. Pretreatment with ISO or IL-13 decreased ISO-induced cAMP generation compared with ISO for 10 minutes alone paralleled by increases in β2AR and GRK2 phosphorylation. GRK2 associated with PEBP1 after 10 minutes of ISO in association with low phosphorylated GRK2 (pGRK2) levels. In contrast, in the presence of IL-13 plus ISO (10 minutes), binding of GRK2 to PEBP1 decreased, whereas 15LO1 binding and pGRK2 levels increased. 15LO1 knockdown restored ISO-induced cAMP generation. These findings were recapitulated in freshly brushed HAECs from cells and tissue of asthmatic patients. IL-13 treatment of HAECs leads to β2AR desensitization, which involves 15LO1/PEBP1 interactions to free GRK2, and allows it to phosphorylate (and desensitize) β2ARs, suggesting that the beneficial effects of β2-agonists could be blunted in patients with type 2 associated asthma." @default.
• W2009050298 created "2016-06-24" @default.
• W2009050298 creator A5029667558 @default.
• W2009050298 creator A5041699601 @default.
• W2009050298 creator A5050793109 @default.
• W2009050298 creator A5057676970 @default.
• W2009050298 creator A5061211681 @default.
• W2009050298 creator A5066244090 @default.
• W2009050298 creator A5071910808 @default.
• W2009050298 creator A5072739933 @default.
• W2009050298 date "2015-05-01" @default.
• W2009050298 modified "2023-10-15" @default.
• W2009050298 title "IL-13 desensitizes β2-adrenergic receptors in human airway epithelial cells through a 15-lipoxygenase/G protein receptor kinase 2 mechanism" @default.
• W2009050298 cites W1483189363 @default.
• W2009050298 cites W181404997 @default.
• W2009050298 cites W1933410007 @default.
• W2009050298 cites W1963640930 @default.
• W2009050298 cites W1967165515 @default.
• W2009050298 cites W1969330410 @default.
• W2009050298 cites W1975403276 @default.
• W2009050298 cites W1978071510 @default.
• W2009050298 cites W1979293072 @default.
• W2009050298 cites W1979580827 @default.
• W2009050298 cites W1990448891 @default.
• W2009050298 cites W1990813403 @default.
• W2009050298 cites W1990951259 @default.
• W2009050298 cites W1997619217 @default.
• W2009050298 cites W1998942760 @default.
• W2009050298 cites W2001051671 @default.
• W2009050298 cites W2014473048 @default.
• W2009050298 cites W2021701428 @default.
• W2009050298 cites W2026933806 @default.
• W2009050298 cites W2027239096 @default.
• W2009050298 cites W2034379667 @default.
• W2009050298 cites W2040911711 @default.
• W2009050298 cites W2043943442 @default.
• W2009050298 cites W2057783001 @default.
• W2009050298 cites W2064306453 @default.
• W2009050298 cites W2070079663 @default.
• W2009050298 cites W2078077815 @default.
• W2009050298 cites W2088495958 @default.
• W2009050298 cites W2089185822 @default.
• W2009050298 cites W2097098587 @default.
• W2009050298 cites W2097491679 @default.
• W2009050298 cites W2117701544 @default.
• W2009050298 cites W2121774438 @default.
• W2009050298 cites W2127482775 @default.
• W2009050298 cites W2128176979 @default.
• W2009050298 cites W2128518753 @default.
• W2009050298 cites W2134436842 @default.
• W2009050298 cites W2136576396 @default.
• W2009050298 cites W2136627244 @default.
• W2009050298 cites W2142242441 @default.
• W2009050298 cites W2150035260 @default.
• W2009050298 cites W2165694323 @default.
• W2009050298 cites W2336934671 @default.
• W2009050298 cites W2396582153 @default.
• W2009050298 cites W3025827099 @default.
• W2009050298 cites W4211006694 @default.
• W2009050298 cites W4255337810 @default.
• W2009050298 doi "https://doi.org/10.1016/j.jaci.2015.02.006" @default.
• W2009050298 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4426258" @default.
• W2009050298 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25819984" @default.
• W2009050298 hasPublicationYear "2015" @default.
• W2009050298 type Work @default.
• W2009050298 sameAs 2009050298 @default.
• W2009050298 citedByCount "21" @default.
• W2009050298 countsByYear W20090502982016 @default.
• W2009050298 countsByYear W20090502982017 @default.
• W2009050298 countsByYear W20090502982018 @default.
• W2009050298 countsByYear W20090502982019 @default.
• W2009050298 countsByYear W20090502982020 @default.
• W2009050298 countsByYear W20090502982021 @default.
• W2009050298 countsByYear W20090502982022 @default.
• W2009050298 countsByYear W20090502982023 @default.
• W2009050298 crossrefType "journal-article" @default.
• W2009050298 hasAuthorship W2009050298A5029667558 @default.
• W2009050298 hasAuthorship W2009050298A5041699601 @default.
• W2009050298 hasAuthorship W2009050298A5050793109 @default.
• W2009050298 hasAuthorship W2009050298A5057676970 @default.
• W2009050298 hasAuthorship W2009050298A5061211681 @default.
• W2009050298 hasAuthorship W2009050298A5066244090 @default.
• W2009050298 hasAuthorship W2009050298A5071910808 @default.
• W2009050298 hasAuthorship W2009050298A5072739933 @default.
• W2009050298 hasBestOaLocation W20090502981 @default.
• W2009050298 hasConcept C104317684 @default.
• W2009050298 hasConcept C126322002 @default.
• W2009050298 hasConcept C134018914 @default.
• W2009050298 hasConcept C135285700 @default.
• W2009050298 hasConcept C153911025 @default.
• W2009050298 hasConcept C170493617 @default.
• W2009050298 hasConcept C173396325 @default.
• W2009050298 hasConcept C184235292 @default.
• W2009050298 hasConcept C22615655 @default.
• W2009050298 hasConcept C55493867 @default.
• W2009050298 hasConcept C67705224 @default.
• W2009050298 hasConcept C71924100 @default.
• W2009050298 hasConcept C78976303 @default.

• next